Profound Medical Corp. (PROF) News
Filter PROF News Items
PROF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROF News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision |
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceTORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA. The presentation will be |
Chairman of the Board & CEO of Profound Medical Picks Up 3.7% More StockInvestors who take an interest in Profound Medical Corp. ( TSE:PRN ) should definitely note that the Chairman of the... |
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common SharesTORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, before d |
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common SharesBASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 4,666,700 common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The gross proceeds of the Offering to Profound, before de |
Profound Medical Announces Proposed Public Offering of Common SharesBASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). In addition, Profound expects to grant the underwriters of the Offering a 30-day option to purchase up to an |
Profound Medical, Siemens Healthineers enter co-sales, co-marketing agreementProfound Medical (PROF) entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers (SIEGY) pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound’s TULSA-PRO system and consumables with Siemens Healthineers’ Magnetom Free.Max magnetic resonance scanner. Subject to the completion of the compatibility process of TULSA-PRO and Magnetom Free.Max, the companies currently expect to initiate sales of the total p |
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that |
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetingsTORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce the unveiling of its third TULSA-AI® |
Profound Medical to Participate in the Stifel 2024 Healthcare ConferenceTORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 9:45 a.m. Eastern Time in NYC. The presentation will be broadcast live and archive |